Nowadays, the pharmacological treatment of obesity has increased its significance due to the failure of conventional obesity treatments. Thus, Orlistat which is a lipase inhibitor is being used as an anti-obesity medication in many countries. In this study, the effect of Orlistat on weight loss and metabolic parameters in Turkish female patients was evaluated. Female patients with diagnosis of obesity who were followed up in Kutahya Training and Research Hospital were evaluated via retrospective observation. A total of 100 patients with body mass index (BMI-kg/m2) of > 40, who were regularly followed up every month and compliant with their treatment (diet, exercise and orlistat) were included in the study. Monthly values of weight loss and BMI, along with baseline - 12th week values of fasting blood glucose, insulin, glycated hemoglobin (HBA1c), lipid profile, creatinine, aspartate aminotransferase, alanine aminotransferase and thyroid- stimulating hormone of patients who received orlistat 120 mg three times a day for 12 weeks in addition to diet and exercise,were evaluated. Mean weight loss values of the patients using orlistat in the 1st, 2nd and 3rd month were found as - 3.6 ± 0.5 kg, -2.2 ± 0.1 kg and -1.8 kg, respectively (p
Key words: Orlistat, obesity, effectiveness, safety
|
